Bile acids and sphingolipids in non-alcoholic fatty liver disease DOI Creative Commons
Kaitlyn G. Jackson, Grayson W. Way, Huiping Zhou

et al.

Chinese Medical Journal, Journal Year: 2022, Volume and Issue: 135(10), P. 1163 - 1171

Published: May 20, 2022

Abstract Non-alcoholic fatty liver disease (NAFLD) is one of the fastest-growing diseases, and its global prevalence estimated to increase >50% by 2030. NAFLD comorbid with metabolic syndrome, obesity, type 2 diabetes, insulin resistance. Despite extensive research efforts, there are no pharmacologic or biological therapeutics for treatment NAFLD. Bile acids sphingolipids well-characterized signaling molecules. Over last few decades, researchers have uncovered potential mechanisms which bile regulate hepatic lipid metabolism. Dysregulation acid sphingolipid metabolism has been linked steatosis, inflammation, fibrosis in patients This clinical observation recapitulated animal models, well-accepted experts hepatology field. Recent transcriptomic lipidomic studies also show that important players pathogenesis Moreover, identification as activators sphingolipid-mediated pathways established a novel theory biology. In this review, we summarize recent advances understanding contributors A better pathologic effects mediated will facilitate development new diagnostic therapeutic strategies

Language: Английский

MAFLD: How is it different from NAFLD? DOI Creative Commons
Cameron Gofton,

Yadhavan Upendran,

Ming‐Hua Zheng

et al.

Clinical and Molecular Hepatology, Journal Year: 2022, Volume and Issue: 29(Suppl), P. S17 - S31

Published: Nov. 29, 2022

“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer related systemic metabolic dysregulation. The name change from nonalcoholic (NAFLD) MAFLD comes with a simple set of criteria enable easy diagnosis at bedside for general medical community, including primary care physicians. Since introduction term, there have been key areas which superiority over traditional NAFLD terminology has demonstrated, risk and extrahepatic mortality, associations, identifying high-risk individuals. Additionally, adopted by number leading pan-national national societies due its concise diagnostic criterion, removal requirement exclude concomitant diseases, reduction stigma associated this condition. current article explores differences between diagnosis, benefit, some potential limitations, how opened up new fields research.

Language: Английский

Citations

239
Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease DOI
Soo Lim, Jin‐Wook Kim, Giovanni Targher

et al.

Trends in Endocrinology and Metabolism, Journal Year: 2021, Volume and Issue: 32(7), P. 500 - 514

Published: May 8, 2021

Language: Английский

Citations

151
Association of metabolic dysfunction-associated fatty liver disease with kidney disease DOI
Ting-Yao Wang,

Rui-Fang Wang,

Zhi-Ying Bu

et al.

Nature Reviews Nephrology, Journal Year: 2022, Volume and Issue: 18(4), P. 259 - 268

Published: Jan. 10, 2022

Language: Английский

Citations

151
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease DOI
Gong Feng, Luca Valenti, Vincent Wai‐Sun Wong

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 21(1), P. 46 - 56

Published: Oct. 5, 2023

Language: Английский

Citations

103
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention DOI Creative Commons
Xiaodong Zhou, Jingjing Cai, Giovanni Targher

et al.

Cardiovascular Diabetology, Journal Year: 2022, Volume and Issue: 21(1)

Published: Dec. 3, 2022

The newly proposed term "metabolic dysfunction-associated fatty liver disease" (MAFLD) is replacing the old "non-alcoholic (NAFLD) in many global regions, because it better reflects pathophysiology and cardiometabolic implications of this common disease. change terminology from NAFLD to MAFLD not simply a single-letter an acronym, since defined by set specific positive diagnostic criteria. In particular, definition specifically incorporates within classification recognized cardiovascular risk factors. Although convincing evidence supports significant association between both MAFLD, with increased CVD morbidity mortality, neither nor have received sufficient attention Cardiology community. fact, there paucity scientific guidelines focusing on burdensome disease professional societies. This Perspective article discusses rationale clinical relevance for Cardiologists definition.

Language: Английский

Citations

100
An international multidisciplinary consensus statement on MAFLD and the risk of CVD DOI Open Access
Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne

et al.

Hepatology International, Journal Year: 2023, Volume and Issue: 17(4), P. 773 - 791

Published: May 19, 2023

Language: Английский

Citations

91
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease DOI Open Access
Dan‐Qin Sun, Giovanni Targher, Christopher D. Byrne

et al.

HepatoBiliary Surgery and Nutrition, Journal Year: 2023, Volume and Issue: 12(3), P. 386 - 403

Published: Feb. 24, 2023

With the rising global prevalence of fatty liver disease related to metabolic dysfunction, association this common condition with chronic kidney (CKD) has become increasingly evident. In 2020, more inclusive term dysfunction-associated (MAFLD) was proposed replace non-alcoholic (NAFLD). The observed between MAFLD and CKD our understanding that can be a consequence underlying dysfunction support notion individuals are at higher risk having developing compared those without MAFLD. However, date, there is no appropriate guidance on in Furthermore, been little attention paid link Nephrology community.Using Delphi-based approach, multidisciplinary panel 50 international experts from 26 countries reached consensus some open research questions regarding CKD.This statement provided epidemiology, mechanisms, management treatment CKD, as well relationship severity which establish framework for early prevention these two interconnected diseases.

Language: Английский

Citations

59
Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta‐analysis: Focusing on the non‐overlap groups DOI
Ibrahim Ayada, Laurens A. van Kleef,

Louise J. M. Alferink

et al.

Liver International, Journal Year: 2021, Volume and Issue: 42(2), P. 277 - 287

Published: Dec. 25, 2021

The applicability of the novel metabolic dysfunction associated fatty liver disease (MAFLD) definition has been studied in numerous cohorts and compared to non-alcoholic (NAFLD). No consensus reached on which is preferred. Therefore, this meta-analysis aims compare epidemiological clinical features NAFLD MAFLD general non-general population.We searched Medline, Embase Web Science for studies comparing NAFLD. Based status, following subgroups were investigated health: overlap (FLD), NAFLD-only MAFLD-only. Data pooled using random-effects models.We included 17 comprising 9 808 677 individuals. In population, was present 33.0% (95% CI 29.7%-36.5%) 29.1% 27.1%-31.1%). Among those with FLD, 4.0% 2.4%-6.4%) did not meet criteria but had (NAFLD-only) 15.1% 11.5%-19.5%) exclusively captured by (MAFLD-only). Notably, MAFLD-only group at significantly increased risk fibrosis (RR 4.2; 95% 1.3-12.9) higher alanine aminotransferase (mean difference: 8.0 U/L, 2.6-13.5) aspartate 6.4 3.0-9.7), NAFLD-only. Similar results obtained among population.Metabolic are highly prevalent considerable between them. However, NAFLD, more individuals additionally identified than missed. Importantly, criteria, damage identified. superior a population level.

Language: Английский

Citations

89
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? DOI Creative Commons
Seong Hee Kang, Yuri Cho, Soung Won Jeong

et al.

Clinical and Molecular Hepatology, Journal Year: 2021, Volume and Issue: 27(2), P. 257 - 269

Published: March 22, 2021

There is some dissatisfaction with the term “nonalcoholic fatty liver disease (NAFLD),” which overemphasizes alcohol and underemphasizes importance of metabolic risk factors in this disease. Recently, a consensus recommended “metabolic (dysfunction)-associated (MAFLD)” as more appropriate to describe diseases (FLD) associated dysfunction. During definition change from NAFLD MAFLD, subjects FLD abnormalities, together other etiologies such alcohol, virus, or medication who have been excluded criteria, were added MAFLD while but without abnormality, included criteria. This means that there an emphasis on dysfunction may underestimate prognostic value hepatic steatosis itself, whereas criteria might better identify are at higher cardiovascular outcomes. However, non-metabolic missed diagnosis, their potential can be cause future diseases. Although huge controversies remain, review focused summarizing recent studies compared clinical characteristics between MAFLD.

Language: Английский

Citations

77
Recent advances in lean NAFLD DOI Open Access

Ruohui Xu,

Jiashu Pan,

Wenjun Zhou

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2022, Volume and Issue: 153, P. 113331 - 113331

Published: June 29, 2022

As the predominant type of chronic liver disease, growing prevalence nonalcoholic fatty disease (NAFLD) has become a concern worldwide. Although obesity plays most pivotal role in NAFLD, approximately 10–20% individuals with NAFLD who are not overweight or obese (BMI < 25 kg/m2, BMI 23 kg/m2 Asians) have "lean NAFLD." Lean lower diabetes, hypertension, hypertriglyceridemia, central obesity, and metabolic syndrome than nonlean but higher fibrosis scores rates cardiovascular morbidity all-cause mortality advanced stages. The pathophysiological mechanisms lean remain poorly understood. Studies shown that is more correlated factors such as environmental, genetic susceptibility, epigenetic regulation. This review will examine way which research progress characteristic explore function modification to provide basis for clinical treatment diagnosis NAFLD.

Language: Английский

Citations

64